转化生长因子β1作为肺癌放射性肺毒性和治疗反应的预测生物标志物:系统综述与荟萃分析
该系统综述与荟萃分析纳入9项前瞻性研究共857例接受放疗的肺癌患者,评估转化生长因子β1(TGF-β1)对放射性肺毒性(RILT)和治疗反应的预测价值。TGF-β1预测RILT的汇总曲线下面积为0.74,发生RILT者TGF-β1比值显著更高(均差0.89),比值>1者不良结局风险增加4.51倍。TGF-β1比值监测有助于肺癌放疗风险分层。
要点
- TGF-β1预测RILT的汇总AUC为0.74,提示具有良好预测效能。
- 发生RILT者TGF-β1比值较无毒性者高0.89(95%CI 0.67-1.11)。
- TGF-β1比值>1者不良结局风险增加4.51倍,RILT风险比为5.29。
核心结论
- TGF-β1比值监测可有效对肺癌放疗患者进行放射性毒性风险分层,支持其用于个体化放疗计划。
- TGF-β1对治疗反应的预测价值仅来自1项研究的初步证据,需更大队列验证。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,检索PubMed、Embase、Scopus和Cochrane Library截至2025年8月。
- 纳入9项前瞻性研究,共857例接受放疗的肺癌患者,使用QUIPS工具进行质量评估,采用随机效应模型计算汇总估计值。
主要发现
- TGF-β1预测RILT的汇总AUC为0.74(95%CI 0.66-0.82)。
- 发生RILT者TGF-β1比值显著高于无毒性者,均差为0.89(95%CI 0.67-1.11,P<.0001)。
- TGF-β1比值>1识别不良结局风险增加4.51倍(95%CI 2.95-6.90,P<.0001),RILT风险分层RR为5.29(95%CI 2.53-11.07)。
- 1项研究初步显示TGF-β1预测治疗反应的RR为4.03(95%CI 2.18-7.45)。
关键数值与推荐
- TGF-β1比值阈值>1用于识别不良结局高风险患者。
- TGF-β1预测RILT的汇总AUC为0.74(95%CI 0.66-0.82)。
临床怎么用
- 可考虑监测TGF-β1比值对肺癌放疗患者进行RILT风险分层,辅助个体化放疗计划制定。
- TGF-β1比值>1提示不良结局风险升高,需加强毒性监测。
- TGF-β1对治疗反应的预测尚未确立,不应常规用于治疗反应预测。
局限性
- 纳入研究数量有限(9项),治疗反应预测证据仅来自1项研究。
- TGF-β1预测治疗反应的价值需更大规模前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-induced lung toxicity (RILT) and variable treatment responses limit the effectiveness of radiation therapy in patients with lung cancer. Transforming growth factor-beta 1 (TGF-β1) has emerged as a potential predictive biomarker, but inconsistent findings across studies have limited its clinical implementation. METHODS AND MATERIALS: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, searching PubMed, Embase, Scopus, and the Cochrane Library through August 2025. Studies investigating TGF-β1 as a predictor of RILT or treatment response in patients with lung cancer receiving radiation therapy were included. Quality assessment used the Quality in Prognosis Studies tool. Random-effects models calculated pooled estimates for area under the curve, mean differences, and risk ratios. RESULTS: Nine prospective studies encompassing 857 patients with lung cancer were included. TGF-β1 demonstrated good predictive performance for RILT with a pooled area under the curve of 0.74 (95% confidence interval [CI], 0.66-0.82). Patients developing RILT showed significantly higher TGF-β1 ratios compared with those without toxicity (mean difference, 0.89, 95% CI, 0.67-1.11, P < .0001). A TGF-β1 ratio threshold >1 identified patients at 4.51-fold increased risk of adverse outcomes (95% CI, 2.95-6.90, P < .0001), with particularly strong performance for RILT risk stratification (risk ratio [RR], 5.29, 95% CI, 2.53-11.07). Preliminary evidence from 1 study suggests potential utility for predicting treatment response (RR, 4.03, 95% CI, 2.18-7.45), requiring validation in larger cohorts. CONCLUSIONS: TGF-β1 ratio monitoring enables effective risk stratification for radiation toxicity in patients with lung cancer, supporting its clinical implementation for personalized radiation therapy planning. Further prospective studies are needed to confirm its predictive value for treatment response.
引用
- Feng LC, Lin CM, Tseng YC, et al. Transforming Growth Factor-Beta 1 as a Predictive Biomarker for Radiation-Induced Lung Toxicity and Treatment Response in Lung Cancer: A Systematic Review and Meta-analysis. Adv Radiat Oncol. 2026. PMID: 42100442. doi:10.1016/j.adro.2026.102049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。